Skip to Main Content

Celsius Therapeutics, a startup built around sequencing genetic material in thousands of an individual’s cells, announced a new deal with Janssen, Johnson and Johnson’s biotech subsidiary, on Tuesday — a partnership that will be the largest proving ground yet for single-cell RNA sequencing technology.

The partnership — for which financial terms were not disclosed — will give Celsius the chance to test its technology with a far bigger dataset than any company has ever used before. The sheer scale could put a renewed spotlight on single-cell RNA sequencing, which scientists hope could bring about more detailed and precise pictures of how individual genes in individual cells misbehave in a particular condition.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!